Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes an identifiable offering/initiative that is still a smaller part of overall results, with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. Scan transcript for such an offering. They mention PCSB merger, but that's not an offering. They mention private banking (Clarendon Private) - they discuss it. Let's see: "any updates on Clarendon private, what assets are up to or are we getting close to breakeven?" Carl says: "It's funny. We do expect this to breakeven in three years that would be 2.5 years. They're right on track with where we expected. Of course, I always wish that they are more than on track but they're right on track and doing excellent. I think the clients that we're bringing in and the types of assets and clientele that we're attracting is exactly what we wanted. And it's working extremely well with the banks. Our lenders our branch managers have really embraced them and the teams have been doing a great job together. So extremely pleased with how things have started out pretty quickly quite honestly, right out of the gates because it does take time to build that. You meet with clients it doesn't happen overnight, right? So, it's something that we're really seeing a lot of great traction on." This is about Clarendon Private. Is it running ahead of what they prepared for? They say "right on track with where we expected" and "I always wish that they are more than on track" - so not ahead. They say "right out of the gates" but that's just starting quickly, not necessarily ahead of plan. They don't say demand exceeds preparation. Also, no mention of concrete steps to expand capacity, staff, etc. So not both. Other offerings? They mention loan growth, deposits, but that's main business. They mention derivatives and investment volumes - but that's not a specific small offering. They mention PCSB merger - that's a merger, not an offering. Thus, no. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).